MindBio Therapeutics is an innovative company in the field of clinical stage pharmaceutical development, leading the way in the exploration of psychedelic microdosing. The initial drug candidate, LSD, is currently undergoing Phase 1 clinical trials involving microdosing in 80 healthy volunteers. In a pioneering clinical trial, participants are provided with microdoses of LSD to take home following a series of psychological and biometric baseline assessments at the laboratory. The company has recently obtained approval for Phase 2 clinical trials, which involve microdosing LSD in late-stage cancer patients suffering from existential distress, anxiety, and depression.